DIFFERENT DOSE REGIMENS OF THE MOUSE MONOCLONAL-ANTIBODY 17-1A FOR THERAPY OF PATIENTS WITH METASTATIC COLORECTAL-CARCINOMA

  • Authors:
    • P RAGNHAMMAR
    • JE FRODIN
    • AL HJELM
    • J FAGERBERG
    • P WERSALL
    • C LINDEMALM
    • B NILSSON
    • K FOX
    • I MAGNUSSON
    • S EWERTH
    • K THOR
    • E SECHER
    • H MELLSTEDT
  • View Affiliations

  • Published online on: November 1, 1995     https://doi.org/10.3892/ijo.7.5.1049
  • Pages: 1049-1056
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Seventy-one patients with metastatic colorectal carcinoma(CRC) were treated with varying doses of the mouse monoclonal antibody (MAb) 17-1A. One patient achieved a partial remission (PR) (1%) with a survival duration of 114+ months. Further 10 patients showed a minor response (MR) or stable disease > 3 months (SD) (14%). In patients receiving a total dose of MAb17-1A < 2 g the overall response rate was 22% (10/45) (1 PR, 2 MR, 7 SD) while patients treated with a total dose > 2 g had a corresponding figure of 4% (1/26) (1 MR) (p < 0.05). Responding patients (n = 11) survived significantly longer than non-responding patients (n = 60) (median: 20 vs 10 months) (p < 0.0027). In the most intensive treatment group (total 12 g), 14 patients received 500 mg of MAb17-1A tiw for 8 weeks. The frequency and intensity of side-effects were mild and did not cause withdrawal or dose reduction of MAb17-1A, even in the 12 g dose schedule. Patients with a pretreatment ADCC (antibody dependent cellular cytotoxicity) activity above the median of all patients, survived significantly longer than those with a low value (p < 0.05).

Related Articles

Journal Cover

November 1995
Volume 7 Issue 5

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
RAGNHAMMAR P, FRODIN J, HJELM A, FAGERBERG J, WERSALL P, LINDEMALM C, NILSSON B, FOX K, MAGNUSSON I, EWERTH S, EWERTH S, et al: DIFFERENT DOSE REGIMENS OF THE MOUSE MONOCLONAL-ANTIBODY 17-1A FOR THERAPY OF PATIENTS WITH METASTATIC COLORECTAL-CARCINOMA. Int J Oncol 7: 1049-1056, 1995
APA
RAGNHAMMAR, P., FRODIN, J., HJELM, A., FAGERBERG, J., WERSALL, P., LINDEMALM, C. ... MELLSTEDT, H. (1995). DIFFERENT DOSE REGIMENS OF THE MOUSE MONOCLONAL-ANTIBODY 17-1A FOR THERAPY OF PATIENTS WITH METASTATIC COLORECTAL-CARCINOMA. International Journal of Oncology, 7, 1049-1056. https://doi.org/10.3892/ijo.7.5.1049
MLA
RAGNHAMMAR, P., FRODIN, J., HJELM, A., FAGERBERG, J., WERSALL, P., LINDEMALM, C., NILSSON, B., FOX, K., MAGNUSSON, I., EWERTH, S., THOR, K., SECHER, E., MELLSTEDT, H."DIFFERENT DOSE REGIMENS OF THE MOUSE MONOCLONAL-ANTIBODY 17-1A FOR THERAPY OF PATIENTS WITH METASTATIC COLORECTAL-CARCINOMA". International Journal of Oncology 7.5 (1995): 1049-1056.
Chicago
RAGNHAMMAR, P., FRODIN, J., HJELM, A., FAGERBERG, J., WERSALL, P., LINDEMALM, C., NILSSON, B., FOX, K., MAGNUSSON, I., EWERTH, S., THOR, K., SECHER, E., MELLSTEDT, H."DIFFERENT DOSE REGIMENS OF THE MOUSE MONOCLONAL-ANTIBODY 17-1A FOR THERAPY OF PATIENTS WITH METASTATIC COLORECTAL-CARCINOMA". International Journal of Oncology 7, no. 5 (1995): 1049-1056. https://doi.org/10.3892/ijo.7.5.1049